Loading...

Blog

Welcome to the Addax Blog, where you will find the necessary insights to be updated on the development of the most relevant scientific research on the subject, and on the results achieved. The articles hereby reported will allow you to better understand the innovative nature of GAF, the importance of a fast replacement of Formalin, and how much our researches had an impact on this issue.

ADDAX Biosciences was born as a spin off of the University of Turin, which contribuited with support to the research activity.

bandiera unione europea

Our company has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No 8157692.

The project “GAF – Towards a hospital without Formalin” is realized thanks to the co-financing of POR FESR Piemonte 2014-2020, Ob.1 – “Research, technological development and innovation, I.1.b.4.1 “Support for creation and consolidation of innovative start-ups with a high intensity of application and knowledge and research spin-off initiatives”.

The project aims to validate, produce and market GAF, a histological fixative without carcinogenicity, that works as a substitute to Formalin. Achieving the project’s objectives will improve the working conditions of health and research professionals, protecting them from the risk of developing occupational diseases caused by inhaling Formalin vapours.

DISCLAIMER!

The information contained in this section is intended exclusively for Healthcare Professionals, in compliance with the Italian legislation, specifically with Art. 21 of the Decreto Legislativo 24 February 1997, n. 46, and the “Guidelines of the Ministry of Health” issued on the 17 February 2010, 28 March 2013 and 20 December 2017. If you intend to access the information, you have to declare and confirm to be a Healthcare Professional by clicking on this disclaimer.